A group of researchers from the Netherlands worked on vaccines containing TLR-ligands (TLR-L) that covalently bound to antigenic SLP, and successfully demonstrated their capacity to induce the antigen-specific CD8+ and CD4+ T cell responses required for anti-tumor effects in preclinical studies [150,151]. Here, CD4 is linked to neoplasm.